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Abstract
Background: The autism spectrum disorders (ASDs) are complex neurodevelopmental disorders that result in
severe and pervasive impairment in the development of reciprocal social interaction and verbal and nonverbal
communication skills. In addition, individuals with ASD have stereotypical behavior, interests and activities. Rare
mutations of some genes, such as neuroligin (NLGN) 3/4, neurexin (NRXN)1 ,SHANK3, MeCP2 and NHE9, have been
reported to be associated with ASD. In the present study, we investigated whether alterations in mRNA expression
levels of these genes could be found in lymphoblastoid cell lines derived from patients with ASD.
Methods: We measured mRNA expression levels of NLGN3/4, NRXN1, SHANK3, MeCP2, NHE9 and AKT1 in
lymphoblastoid cells from 35 patients with ASD and 35 healthy controls, as well as from 45 patients with
schizophrenia and 45 healthy controls, using real-time quantitative reverse transcriptase polymerase chain reaction
assays.
Results: The mRNA expression levels of NLGN3 and SHANK3 normalized by b-actin or TBP were significantly
decreased in the individuals with ASD compared to controls, whereas no difference was found in the mRNA
expression level of MeCP2, NHE9 or AKT1. However, normalized NLGN3 and SHANK3 gene expression levels were
not altered in patients with schizophrenia, and expression levels of NLGN4 and NRXN1 mRNA were not
quantitatively measurable in lymphoblastoid cells.
Conclusions: Our results provide evidence that the NLGN3 and SHANK3 genes may be differentially expressed in
lymphoblastoid cell lines from individuals with ASD compared to those from controls. These findings suggest the
possibility that decreased mRNA expression levels of these genes might be involved in the pathophysiology of
ASD in a substantial population of ASD patients.
Background
Autism spectrum disorder (ASD), also known as perva-
sive developmental disorder (PDD), is defined as severe
and pervasive impairments in the development of reci-
procal social interaction and verbal and nonverbal com-
munication skills. These disorders are also characterized
by stereotypical behavior, interests and activities. The
lifetime morbidity rate of ASD is 0.2% to 1.0% across
studies [1]. In addition, twin and family studies of ASD
have demonstrated a high heritability of approximately
90% [2], indicating that ASD is a heterogeneous condi-
tion that is likely to result from the combined effects of
multiple genetic factors interacting with environmental
factors. Recent genetic studies have identified several
vulnerability loci and genetic mutations that cause ASD.
One of the most striking revelations is the important
role of genes that encode proteins at the neuronal
synapse [3].
Rare mutations in the neuroligin 3 (NLGN3) and neu-
roligin 4 (NLGN4) genes, which map to chromosomes
Xq13 and Xp22.3, have been reported in some patients
with ASD and other neurodevelopmental impairments
[4-8]. A particular mutation of NLGN3 (Arg451Cys) is
known to cause a defect in protein processing of
NLGN3 [9]. In addition, a particular mutation of
NLGN4 (1186insT) causes a frameshift mutation that
leads to premature termination of NLGN4 (D396X),
resulting in a loss of 421 amino acids (51% of the
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localized cell adhesion molecules, play a crucial role in
organizing excitatory glutamatergic and inhibitory
GABAergic synapses in the mammalian brain by inter-
acting with presynaptic b-neurexins (NRXN), thereby
triggering the formation of functional presynaptic struc-
tures in contacting axons [10]. Mutations of the neur-
exin 1 (NRXN1) gene, at the chromosome locus 2q32,
have been found in individuals with ASD [11-14].
Furthermore, de novo copy number variation analysis
revealed deletion of the NRXN1-containing gene region
in ASD [15]. The binding of NRXN1 and NLGN genes
mediates synaptic development [16]. Interestingly, a
mutation of NLGN3 results in a disruption of the ability
to bind to NRXN [9]. In addition, neuroligins interact
with a postsynaptic scaffolding protein, SHANK3, which
is also implicated in ASD [17] and is located on the
telomeric terminal of chromosome 22q13.3. Shank pro-
teins couple neurotransmitter receptors, ion channels
and other membrane proteins to the actin cytoskeleton
and G protein-coupled signaling pathways, and they also
play a role in synapse formation and dendritic spine
maturation [18]. Deletion or translocation of the geno-
mic locus, which includes the SHANK3 gene, and de
novo mutations of the SHANK3 gene result in prema-
ture stop codons and have been found in ASD
[17,19,20].
In a study of consanguineous autism families, Morrow
et al. [21] observed a relationship between ASD and
alterations in the sodium/hydrogen exchanger 9 (NHE9)
gene. Specifically, they found a nonsense mutation in
patients with ASD that is a heterozygous CGA-to-TGA
transition, changing arginine 423 to a stop codon [21].
The NHE9 gene is located on chromosome 3q24 and is
one of the families of Na
+/H
+ exchangers that regulate
ion flux across membranes [22]. Rett syndrome is
another PDD, and the methyl-CpG-binding protein 2
(MeCP2) gene is a causal gene for Rett syndrome.
MeCP2 is a transcriptional repressor that binds to
methylated CpG dinucleotides generally located at gene
promoters and recruits histone deacetylase 1 and other
proteins involved in chromatin repression [23]. De novo
mutations of the MeCP2 gene located on chromosome
Xp28 occur in 80% of female patients with Rett syn-
drome [24]. Some evidence of dysregulation of the phos-
phatidylinositol 3-kinase (PI3K)/AKT pathway is
implicated in ASD, despite the fact that no mutation
which causes ASD has been reported in association with
the AKT1 gene. The expression and phosphorylation
and/or activation of AKT were found to be decreased in
the autistic brain [25]. The PTEN gene (phosphatase
and tensin homolog deleted on chromosome 10) is a
major negative regulator of the PI3K/AKT pathway, and
PTEN mutations have been linked to ASD [26].
Recently, several studies have suggested that lympho-
blastoid cells can be used to detect biologically plausible
correlations between candidate genes and neuropsychia-
tric diseases, including Rett syndrome [27], nonspecific
X-linked mental retardation [28], bipolar disorder [29],
fragile X syndrome [30,31] and dup(15q) [32]. In the
present study, we compared mRNA expression levels of
various genes in blood-derived lymphoblastoid cells
from individuals with ASD and healthy controls.
Methods
Participants
We obtained mRNA samples from patients with ASD,
patients with schizophrenia and healthy controls from
the research bioresource of the Human Brain Phenotype
Consortium in Japan (http://www.sp-web.sakura.ne.jp/
consortium.html). The ASD cohort consisted of
35 patients with ASD and healthy controls (Table 1).
Patients with ASD and patients with schizophrenia were
recruited from both outpatient and inpatient services at
O s a k aU n i v e r s i t yH o s p i t a l .Each ASD patient was diag-
nosed by at least two trained child psychiatrists and/or
child neurologists according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition-
Text Revision (DSM-IV-TR) criteria based on unstruc-
tured or semistructured behavioral observations of the
patients and interviews with the patients and their par-
ents or caregivers. During the interview, the Pervasive
Developmental Disorders Autism Society Japan Rating
S c a l e( P A R S )[ 3 3 ]a n dt h eJ a p a n e s ev e r s i o no ft h e
Asperger’s Questionnaire [34] were used to assist in the
evaluation of ASD-specific behaviors and symptoms.
PARS is a semistructured interview that is composed of
Table 1 Demographic information for the ASD and
control cohorts
a
Demographics ASD
(n = 35)
Controls
(n = 35)
P value
Sex, M/F 27/8 26/9 c
2 = 0.078 (1, N =
70), P = 0.78
Mean age, years ( ± SD) 12.9 (12.4) 34.8 (9.7) U = 86, P = 0.60 ×
10
-9, Z = -6.19
Age range, years 3 to 63 21 to 65
Number of ASD
(with IQ < 70)
35 (11) 0
Number of Autism
(with IQ < 70)
20 (10) -
Number of Asperger’s
syndrome (with IQ < 70)
11 (0) -
Number with PDD-NOS
(with IQ < 70)
4 (1) -
ASD: autism spectrum disorder, M: male, F: female, IQ: intelligence quotient;
PDD-NOS: pervasive developmental disorder not otherwise specified. Data are
means ± SD unless otherwise specified. Differences in clinical characteristics
were analyzed using the c
2 test for gender and the Mann-Whitney U test for
age.
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children with PDD, which was developed by the Autism
Society Japan. The clinicians who diagnosed the indivi-
duals were trained in the use of PARS. Twenty indivi-
duals met the full criteria for autistic disorder, 11 met the
criteria for Asperger syndrome and four for PDD-not
otherwise specified (PDD-NOS). Among the patients
with ASD, 11 had a low intelligence quotient (IQ) ( < 70).
The schizophrenia cohort consisted of 45 patients with
schizophrenia and 45 age- and sex-matched healthy con-
trols (Table 2). Each patient with schizophrenia received
a consensus diagnosis by at least two trained psychiatrists
according to the DSM-IV-TR criteria using the struc-
tured clinical interview (SCID) for DSM-IV.
A detailed description of healthy controls was given in
previous reports [35,36]. Briefly, controls were biologi-
cally unrelated Japanese participants. Healthy controls
were screened using the SCID for the Diagnostic and
Statistical Manual, Fourth Edition, Axis I Disorders,
Non-Patient version (SCID-I/NP) and were excluded if
they (1) had neurological or medical conditions that
could potentially affect the central nervous system, (2)
had any psychiatric diseases and/or received psychiatric
medication, (3) had first- or second-degree relatives with
psychiatric disease or (4) presented with an IQ < 70. IQ
data were collected using the Japanese version of the
full-scale Wechsler Adult Intelligence Scale (WAIS)-III
or the full-scale Wechsler Intelligence Scale for Chil-
dren-Third Edition (WISC-III) [37,38].
Following description of the study, written informed
consent was obtained from each individual (or, when
appropriate, his/her guardians). This study was carried
out in accordance with the World Medical Association’s
Declaration of Helsinki and was approved by the ethics
committee at Osaka University.
Immortalization of lymphocytes and RNA extraction
Isolation of lymphocytes from blood and lymphocyte
immortalization using Epstein-Barr virus (EBV) were
entrusted to SRL of Tokyo, Japan. Immortalized,
patient-derived lymphocytes were grown in culture
media supplemented with 20% fetal bovine serum. Total
RNA was extracted from cell pellets using the RNeasy
Mini Kit (Qiagen K.K., Tokyo, Japan). The total RNA
yield was determined by absorbance at 260 nm, and RNA
quality was analyzed using agarose gel electrophoresis.
DNase treatment and reverse transcriptase reaction
Total RNA was treated with DNase to remove contami-
nating genomic DNA using DNase Treatment &
Removal Reagents (Ambion, Austin, TX, USA) according
to the manufacturer’s protocol. Total RNA (10 μg) trea-
ted with DNase was used in a 50-μL reverse transcriptase
reaction to synthesize cDNA with the SuperScript First-
Strand Synthesis System for RT-PCR (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s protocol.
Briefly, total RNA (10 μg) was denatured with 1 mM
deoxyribonucleotide triphosphate (dNTP) and 5 ng/μL
random hexamers at 65°C for 5 minutes. After the addi-
tion of 10xRT buffer (20 mM Tris-HCl (pH 8.4) and
50 mM KCl final concentration; Invitrogen), MgCl2
(5 mM final concentration), dithiothreitol (10 mM final
concentration), RNaseOUT Recombinant Ribonuclease
Inhibitor (100 U; Invitrogen) and SuperScript III Reverse
Transcriptase (125 U; Invitrogen), the reaction mixture
was incubated at 25°C for 10 minutes, at 42°C for
40 minutes and at 70°C for 15 minutes. RNase H (5 U)
was added to the reaction mixture and incubated at 37°C
for 20 minutes to stop the reaction.
Real-time quantitative RT-PCR
The Pre-Developed TaqMan Assay Reagent kit (Applied
Biosystems, Foster City, CA, USA) was used to measure
mRNA expression levels of NLGN3, NLGN4, NRXN1,
SHANK3, MeCP2, NHE9, AKT1 and housekeeping genes
(b-actin and TBP). Primers were purchased from Applied
Biosystems (gene name: assay ID, transcript ID, target
region; NLGN3: Hs01043809_m1, NM_181303.1, Exon4-
5; NLGN4: Hs00535592_m1, NM_020742.2, Exon1-2;
NRXN1: Hs00985123_m1, NM_001135659.1, Exon22-23;
SHANK3: Hs01586468_m1, NM_001080420.1, Exon22-
23; MECP2: Hs00172845_m1, NM_004992.3, Exon2-3;
NHE9: Hs00543518_m1, NM_173653.3, Exon7-8; AKT1:
Hs00920503_m1, NM_001014432.1, Exon13-14; b-actin:
4326315E, NM_001101, no region indicated; TBP:
4326322E, NM_003194, no region indicated). Expression
levels of these genes were measured by real-time quanti-
tative reverse transcriptase polymerase chain reaction
(qRT-PCR) using an ABI Prism 7900 Sequence Detection
System (Applied Biosystems) with a 384-well format as
previously described [39,40]. Each 20-μLP C Rr e a c t i o n
contained 6 μL of cDNA, 900 nM concentrations of each
primer, a 250 nM concentration of probe and 10 μLo f
Table 2 Demographic information for schizophrenia and
control cohorts
a
Demographics Schizophrenia
(n = 45)
Controls
(n = 45)
P value
Sex, M/F 26/19 26/19 c
2 = 0 (1, N = 90),
P = 1.0
Mean age, years
( ± SD)
37.9 (1.6) 38.1 (1.7) U = 988.5, P = 0.9,
Z = -0.2
Age range, years 21 to 65 21 to 65
Estimated premorbid
IQ (JART50)
100.8 (9.3) 105.4 (8.4) U = 687, P =
0.009, Z = -2.6
M: male, F: female, IQ: intelligence quotient; JART50: Japanese Adult Reading
Test: Japanese version of the National Adult Reading Test. Data are means ±
SD unless otherwise specified. Differences in clinical characteristics were
analyzed using the c
2 test for gender and the Mann-Whitney U test for age.
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Taq Gold DNA Polymerase and AmpErase Uracil N-gly-
cosylase (all from Applied Biosystems), as well as dNTP
with deoxyuridine triphosphate, passive reference and
optimized buffer components. The PCR cycling condi-
tions were 50°C for 2 minutes, 95°C for 10 minutes,
40 cycles of 95°C for 15 seconds and 59°C or 60°C for 1
minute. PCR data were obtained by using Sequence
Detector software (SDS version 2.1; Applied Biosystems)
and quantified using a standard curve method. This
software plotted the real-time fluorescence intensity and
selected the threshold within the linear phase of the
amplicon profile. The software plotted a standard curve
of the cycle at threshold (Ct) (where the fluorescence
generated within a reaction crossed the threshold) ver-
sus the quantity of RNA. All samples were measured
using a single plate per target gene, and their Ct values
were in the linear range of the standard curve. Sample
quantities were predicted by Ct values. Experiments
were typically performed three times in triplicate, and
each gene expression level was taken as the average of
three independent experiments. The individual expres-
sion level of each target gene normalized by a house-
keeping gene (raw target gene expression level divided
by raw housekeeping gene expression level) was used
for statistical analysis.
Statistical analyses
Statistical analyses were carried out using SPSS for Win-
dows version 16.0 software (SPSS Japan Inc., Tokyo,
Japan). Group comparisons of demographic data were
performed using the c
2 test for one categorical variable
(sex) or the Mann-Whitney U test for continuous vari-
ables as appropriate. Differences in mRNA transcript
levels between the groups were analyzed using the
Mann-Whitney U test. The Bonferroni correction for
multiple tests was applied to assess the mRNA tran-
script levels on the number of genes (five). All P values
reported are based on two-tailed tests. Statistical signifi-
cance was defined as P < 0.05.
Results
Standard curves for the seven target genes (NLGN3,
NLGN4, NRXN1, SHANK3, MeCP2, NHE9 and AKT1)
and the two housekeeping genes (b-actin and TBP) were
prepared using serial dilutions (1:4) of pooled cDNA
from 300 ng of total RNA derived from immortalized
lymphoblasts (Figure 1). The R
2 values of the standard
curves were more than 0.99 (NLGN3, MeCP2, NHE9,
AKT1, b-actin and TBP), 0.87 (SHANK3), 0.64 (NRXN1)
and 0.63 (NLGN4). Although the SHANK3 gene expres-
sion was relatively low, it was measurable in our sample.
On the other hand, we did not further analyze NLGN4
and NRXN1 gene expression, as the expression levels of
t h et w og e n e sw e r et o ol o wt oq u a n t i f yu s i n gt h i s
method.
Using immortalized lymphoblastoid cells from 35 indi-
viduals with ASD and 35 controls, we quantified the
mRNA expression levels of the NLGN3, SHANK3,
NHE9, MeCP2 and AKT1 genes normalized by two
housekeeping genes, b-actin and TBP (Figure 2). The
mRNA expression levels of the NLGN3 gene normalized
by b-actin or TBP were decreased by 35% or 26%,
respectively, in individuals with ASD (b-actin: P =
Figure 1 Standard curves for target genes and housekeeping
genes. Standard curves for NLGN3, NLGN4, NRXN1, SHANK3, MeCP2,
NHE9, AKT1 and two housekeeping genes (b-actin and TBP). The
highest quantity represents an amount of cDNA prepared from 300
ng of total RNA in the polymerase chain reaction.
Figure 2 Expression analysis of NLGN3, SHANK3, NHE9, MeCP2
and AKT1 in autism spectrum disorder. Mean relative mRNA
expression level scores normalized by housekeeping gene b-actin
(a) or TBP (b) in the autism spectrum disorder (ASD) group and the
control group are shown. Bars represent the standard error of the
mean. Differences between the groups in expression levels of the
five genes were analyzed by using the Mann-Whitney U test. Post
hoc comparisons were performed by using the Bonferroni
correction. **P < 0.01 and ***P < 0.001.
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levels of the SHANK3 gene normalized by b-actin or
TBP were also decreased in individuals with ASD by
39% or 40%, respectively (b-actin: P = 0.000036; TBP:
P = 0.0061). The mRNA expression levels of the NHE9
gene were increased by 24% (P = 0.052: normalized by
b-actin) and 39% (P = 0.048: normalized by TBP). There
was no significant difference in mRNA expression levels
of the MeCP2 gene normalized by b-actin or TBP
between the two groups (P >0 . 1 ) .T h em R N Ae x p r e s -
sion levels of the AKT1 gene were decreased by 11%
(P = 0.03: normalized by b-actin); however, those levels
were not altered when normalized by TBP (P =0 . 4 5 ) .
After correction for multiple tests, mRNA expression
levels of NLGN3 and SHANK3 remained significantly
lower in individuals with ASD than in healthy controls
(NLGN3: corrected P = 0.0012, normalized by b-actin,
corrected P = 0.0045, normalized by TBP; SHANK3: cor-
rected P = 0.00018, normalized by b-actin, corrected P =
0.03, normalized by TBP). However, the altered expres-
sion level of NHE9 or AKT1 was no longer significant
after the correction for multiple tests (P > 0.1).
We next measured NLGN3 and SHANK3 mRNA
expression levels in immortalized lymphoblastoid cells
from 45 patients with schizophrenia and 45 healthy con-
trols to examine the disease specificity of the differential
expression levels between patients and healthy controls
(Figure 3). We found that the mRNA expression levels
for these two genes normalized by b-actin or TBP were
not significantly different between patients with schizo-
phrenia and healthy controls (P > 0.2). These results
suggest that reduced levels of NLGN3 and SHANK3
mRNA expression might be associated with ASD but
not with schizophrenia.
Discussion
In this study, we found that the mRNA expression levels
of NLGN3 and SHANK3 were significantly lower in indi-
viduals with ASD than in healthy controls. Mutations of
causal genes are rare, and they have been found to be
associated with specific types of ASD. Our findings sug-
gest that not only rare mutations of the causal genes
but also functional alterations in the transcriptional
activity of these genes might be associated with the
pathophysiology of ASD. The NLGN3 and SHANK3
genes are synapse-related genes and were found to be
affected in ASD, whereas other genes, including NHE9
and MeCP2, do not play major roles at the synapse and
were not found to be affected in ASD. These findings
suggest that impairments in synaptic function might be
associated with the pathophysiology of ASD.
Reduced expression of the NLGN3 and SHANK3
genes in lymphoblasts of individuals with ASD is consis-
tent with previous reports indicating that mutations of
these genes cause reduced expression or loss of function
of the protein. Since the NLGN3 gene is located in chro-
mosome X, there may be expressional difference
between genders. However, no significant difference of
NLGN3 gene expression normalized by b-actin or TBP
was observed with regard to gender in healthy controls
or individuals with ASD (P >0 . 0 5 ) .T h i sm i g h tb ed u e
to inactivation of one X chromosome in females [41].
There are several possibilities that might explain the
reduced expression of the NLGN3 and SHANK3 genes
in ASD. First, our sporadic ASD cases might have muta-
tions, polymorphisms or copy number variations in the
NLGN3 or SHANK3 genes, which could result in
reduced expression of these genes. Second, mutations or
polymorphisms in genes that regulate the expression of
NLGN3 or SHANK3 might contribute to the observed
r e d u c t i o ni ne x p r e s s i o no ft h eNLGN3 or SHANK3
genes. To our knowledge, although the regulation of
NLGN3 by other genes has not been reported, there are
some reports in the literature describing the regulation of
SHANK3 gene expression. For example, SHANK3 expres-
sion is regulated by DNA methylation [42,43]. In addition,
SHANK3 is one of the predicted targets of dysregulated
microRNA (miRNA), and altered miRNA expression levels
w e r ef o u n di np o s t m o r t e mb r a i nf r o ma u t i s mp a t i e n t s
[44]. Further epigenetic analyses might elucidate the
mechanisms of reduced SHANK3 expression.
Some findings of gene expression in lymphoblastoid
cell lines are in conflict with those of previous studies.
For example, Beri et al. [42] reported that SHANK3 is
not expressed in EBV-transformed human lymphoblas-
toid cell lines in an investigation of tissue-specific
Figure 3 Expression analysis of the NLGN3 and SHANK3 genes
in patients with schizophrenia. Mean relative mRNA expression
level scores normalized by housekeeping gene b-actin (a) or TBP (b)
in the schizophrenia group and the control group are shown. Bars
represent standard error of the mean. Differences in expression
levels of the two genes between the groups were analyzed by
using the Mann-Whitney U test.
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using lymphoblastoid cells from autism patients, Talebi-
zadeh et al. [8] detected novel splice isoforms of
NLGN4. There are methodological differences between
previous studies and our study. SHANK3 gene expres-
sion in the previous study [42] was analyzed by using a
conventional RT-PCR method; however, we measured
the expression levels of SHANK3 gene by using a real-
time qRT-PCR method (the TaqMan method). Further-
more, the expression level of SHANK3 was relatively
low, which is shown in the standard curve in Figure 1.
It is possible that the sensitivity of our real-time qRT-
PCR method to detect the SHANK3 gene expression
level might be higher than that of a conventional RT-
PCR method. On the other hand, we could not quanti-
tatively measure the NLGN4 and NRXN1 genes by using
the real-time qRT-PCR method. However, there were
slight expressions of these genes in lymphoblastoid cell
lines when we used a large quantity of cDNA for the
real-time qRT-PCR (Figure 1). Unfortunately, the small
expression levels of these genes made it impossible to
quantitatively measure the gene expressions in our sam-
ple. This may explain possible discrepancies of the gene
expression findings of previous studies and our results.
There are several limitations of this study. First, our
positive results might have arisen from sample bias due
to non-age-matched samples, although the Japanese are
a relatively homogeneous population, so the use of non-
age-matched samples is unlikely to explain our findings.
Second, our sample size might not be small for type I
errors but small for type II errors. There is a possibility
of type II errors in mRNA expression differences of
NHE9, MECP2 and AKT1 between individuals with
ASD and healthy controls and expression differences of
NLGN3 and SHANK3 between individuals with schizo-
phrenia and healthy controls. In particular, NHE9 might
be increased in individuals with ASD, as the expression
level of NHE9 was marginally significant before correc-
tion for multiple testing. Thus, replication studies using
a larger sample size are needed before a firm conclusion
can be drawn. Third, we did not perform a mutation
search for the examined genes in our sample to replicate
the association between the examined genes and ASD
and how the causal or risk variants of the genes regulate
the gene expression. As the previous evidence for candi-
date genes of ASD are based on rare mutations and/or
copy number variations of the genes, it might be diffi-
cult to find a mutation in our 35 individuals with ASD
for analysis of the variant effects on the gene expression
in this study. A mutation search study of these candi-
date genes should be done in future studies. Fourth, the
IQ scores in the ASD group were lower than those in
the healthy control group, so reduced gene expression
could be related to lower IQ. However, lower expression
of the NLGN3 or SHANK3 genes was not found in indi-
viduals with schizophrenia who had lower premorbid IQ
scores, and no expression difference was observed in
individuals with ASD and mental retardation versus
individuals with ASD but without mental retardation
(data not shown). Taken together, the reduced gene
expression in ASD might be specific to ASD, although
other neuropsychiatric diseases, such as attention-defi-
cit/hyperactivity disorder, mental retardation, major
depression and bipolar disorder, should be examined in
future studies. The ASD cases in this study were consis-
tent with idiopathic autism diagnosed on the basis of
clinical features. We did not include individuals with
Rett syndrome and the other syndromic autisms, such as
multiple sclerosis, which could explain why we did not
find altered expression of MeCP2 in this cohort. Our
results suggest that the MeCP2 gene may not be associated
with the common pathology of ASD, while NLGN3 and
SHANK3 may be. Because lymphoblastoid cell lines are
not neuronal cells, some of our findings might not reflect
the pathophysiology in ASD brains. Further studies inves-
tigating these limitations are warranted.
Conclusions
Our study reveals reduced levels of NLGN3 and
SHANK3 mRNA expression in lymphoblastoid cell lines
derived from individuals with ASD, but not from those
of individuals with schizophrenia. These results are con-
sistent with findings that rare mutations of these genes
in specific cases cause loss of function, suggesting that
reduction of NLGN3 and SHANK3 mRNA expression
could be related to the pathophysiology of ASD in a
substantial population of patients. Although there are
several limitations present in this study, lymphoblastoid
cell lines may still allow investigation of the pathophy-
siology of ASD. Further analyses are required, such as a
mutation analysis of the NLGN3 and SHANK3 genes
and the genes regulating their expression, in addition to
studies designed to elucidate the mechanisms of this
reduced expression.
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